ABVC BioPharma Inc. (ABVC)
ABVC BioPharma Statistics
Share Statistics
ABVC BioPharma has 12.98M shares outstanding. The number of shares has increased by 22.87% in one year.
| Shares Outstanding | 12.98M |
| Shares Change (YoY) | 22.87% |
| Shares Change (QoQ) | 4.46% |
| Owned by Institutions (%) | 1.78% |
| Shares Floating | 11.24M |
| Failed to Deliver (FTD) Shares | 1.35K |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 186.19K, so 1.43% of the outstanding shares have been sold short.
| Short Interest | 186.19K |
| Short % of Shares Out | 1.43% |
| Short % of Float | 1.67% |
| Short Ratio (days to cover) | 0.7 |
Valuation Ratios
The PE ratio is -0.48 and the forward PE ratio is -1.22. ABVC BioPharma's PEG ratio is 0.01.
| PE Ratio | -0.48 |
| Forward PE | -1.22 |
| PS Ratio | 32.99 |
| Forward PS | 0.3 |
| PB Ratio | 0.6 |
| P/FCF Ratio | -1.18 |
| PEG Ratio | 0.01 |
Enterprise Valuation
ABVC BioPharma Inc. has an Enterprise Value (EV) of 6.76M.
| EV / Earnings | -0.64 |
| EV / Sales | 44.37 |
| EV / EBITDA | -0.83 |
| EV / EBIT | -0.82 |
| EV / FCF | -1.59 |
Financial Position
The company has a current ratio of 0.28, with a Debt / Equity ratio of 0.27.
| Current Ratio | 0.28 |
| Quick Ratio | 0.28 |
| Debt / Equity | 0.27 |
| Total Debt / Capitalization | 21.36 |
| Cash Flow / Debt | -1.86 |
| Interest Coverage | -3.3 |
Financial Efficiency
Return on equity (ROE) is -1.25% and return on capital (ROIC) is -80.83%.
| Return on Equity (ROE) | -1.25% |
| Return on Assets (ROA) | -0.73% |
| Return on Capital (ROIC) | -80.83% |
| Revenue Per Employee | 9.53K |
| Profits Per Employee | -657.23K |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 256.01K |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by -41.53% in the last 52 weeks. The beta is 0.67, so ABVC BioPharma's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | -41.53% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 60.22 |
| Average Volume (20 Days) | 599.51K |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of 152.43K and earned -10.52M in profits. Earnings per share was -2.43.
| Revenue | 152.43K |
| Gross Profit | -149.61K |
| Operating Income | -8.22M |
| Net Income | -10.52M |
| EBITDA | -8.13M |
| EBIT | -8.22M |
| Earnings Per Share (EPS) | -2.43 |
Balance Sheet
The company has 60.16K in cash and 2.28M in debt, giving a net cash position of -2.22M.
| Cash & Cash Equivalents | 60.16K |
| Total Debt | 2.28M |
| Net Cash | -2.22M |
| Retained Earnings | -65.42M |
| Total Assets | 14.46M |
| Working Capital | -4.17M |
Cash Flow
In the last 12 months, operating cash flow was -4.24M and capital expenditures -21.2K, giving a free cash flow of -4.26M.
| Operating Cash Flow | -4.24M |
| Capital Expenditures | -21.2K |
| Free Cash Flow | -4.26M |
| FCF Per Share | -0.98 |
Margins
Gross margin is -98.15%, with operating and profit margins of -5.39K% and -6.9K%.
| Gross Margin | -98.15% |
| Operating Margin | -5.39K% |
| Pretax Margin | -6.99K% |
| Profit Margin | -6.9K% |
| EBITDA Margin | -5.34K% |
| EBIT Margin | -5.39K% |
| FCF Margin | -2.79K% |
Dividends & Yields
ABVC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -352.17% |
| FCF Yield | -47.82% |
Analyst Forecast
Currently there are no analyst rating for ABVC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 25, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 25, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -7.62 |
| Piotroski F-Score | 3 |